#M&A – Page 3 – HEALTHCARE INSIGHTS

Key Development U.S. commercial biopharmaceutical specialists Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have formally entered into a... Read more

Tag: #M&A

Targeted Radiopharmaceuticals & Rare Epilepsy M&A: Jazz Pharmaceuticals Executes $1.32 Billion Acquisition of Actio Biosciences to Acquire First-in-Class Pediatric Precision Therapy

Biopharmaceutical M&A: Biogen Completes Acquisition of RayThera Inc., Expanding Immunology Pipeline with Small-Molecule Assets

Consumer Health & Wellness M&A: Procter & Gamble (P&G) Executes $3.8 Billion Acquisition of Premium Supplement Brand Thorne HealthTech

In Vivo Cell Therapy Breakthrough: Johnson & Johnson Commits $785 Million Upfront to Sail Biomedicines, Securing a $2.58 Billion Acquisition Option for Autoimmune CAR-T Platform

Mega Radiopharmaceutical Merger: Curium Strikes $8 Billion Deal to Acquire Rival Lantheus, Building a Global Theranostics Powerhouse

Neuroscience Consolidation: Supernus and Indivior Agree to All-Stock Merger Creating a $2.2 Billion CNS Biopharma Powerhouse

Billion-Dollar MedTech Buyout: KKR Executes $5.7 Billion All-Cash Take-Private Transaction for Integer Holdings

Blockbuster DAC Acquisition: Johnson & Johnson Deploys $1 Billion to Acquire Firefly Bio, Capturing Pan-KRAS Degrader Platforms for Hard-to-Treat Solid Tumors

Mega-Merger Dynamics: AstraZeneca Holds Preliminary $400 Billion Consolidation Talks With Bristol Myers Squibb (BMY) to Form World’s 4th Largest Pharma Giant

Facebook

Map

Online Members